Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production

Yago Pico de Coaña, Isabel Poschke, Giusy Gentilcore, Yumeng Mao, Maria Nyström, Johan Hansson, Giuseppe V. Masucci, Rolf Kiessling

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Blocking the immune checkpoint molecule CTL antigen-4 (CTLA-4) with ipilimumab has proven to induce long-lasting clinical responses in patients with metastatic melanoma. To study the early response that takes place after CTLA-4 blockade, peripheral blood immune monitoring was conducted in five patients undergoing ipilimumab treatment at baseline, three and nine weeks after administration of the first dose. Along with T-cell population analysis, this work was primarily focused on an in-depth study of the myeloid-derived suppressor cell (MDSC) populations. Ipilimumab treatment resulted in lower frequencies of regulatory T cells along with reduced expression levels of PD-1 at the nine-week time point. Three weeks after the initial ipilimumab dose, the frequency of granulocytic MDSCs was significantly reduced and was followed by a reduction in the frequency of arginase1-producing CD3(-) cells, indicating an indirect in trans effect that should be taken into account for future evaluations of ipilimumab mechanisms of action.

Original languageEnglish
Pages (from-to)158-162
Number of pages5
JournalCancer immunology research
Volume1
Issue number3
DOIs
Publication statusPublished - 1 Sep 2013
Externally publishedYes

Fingerprint

Therapeutics
Antigens
Immunologic Monitoring
Regulatory T-Lymphocytes
Population
Melanoma
ipilimumab
Myeloid-Derived Suppressor Cells
T-Lymphocytes

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. / Pico de Coaña, Yago; Poschke, Isabel; Gentilcore, Giusy; Mao, Yumeng; Nyström, Maria; Hansson, Johan; Masucci, Giuseppe V.; Kiessling, Rolf.

In: Cancer immunology research, Vol. 1, No. 3, 01.09.2013, p. 158-162.

Research output: Contribution to journalArticle

Pico de Coaña, Yago ; Poschke, Isabel ; Gentilcore, Giusy ; Mao, Yumeng ; Nyström, Maria ; Hansson, Johan ; Masucci, Giuseppe V. ; Kiessling, Rolf. / Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. In: Cancer immunology research. 2013 ; Vol. 1, No. 3. pp. 158-162.
@article{69d02c2c48a44bd9802dc6ff80a2ab57,
title = "Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production",
abstract = "Blocking the immune checkpoint molecule CTL antigen-4 (CTLA-4) with ipilimumab has proven to induce long-lasting clinical responses in patients with metastatic melanoma. To study the early response that takes place after CTLA-4 blockade, peripheral blood immune monitoring was conducted in five patients undergoing ipilimumab treatment at baseline, three and nine weeks after administration of the first dose. Along with T-cell population analysis, this work was primarily focused on an in-depth study of the myeloid-derived suppressor cell (MDSC) populations. Ipilimumab treatment resulted in lower frequencies of regulatory T cells along with reduced expression levels of PD-1 at the nine-week time point. Three weeks after the initial ipilimumab dose, the frequency of granulocytic MDSCs was significantly reduced and was followed by a reduction in the frequency of arginase1-producing CD3(-) cells, indicating an indirect in trans effect that should be taken into account for future evaluations of ipilimumab mechanisms of action.",
author = "{Pico de Coa{\~n}a}, Yago and Isabel Poschke and Giusy Gentilcore and Yumeng Mao and Maria Nystr{\"o}m and Johan Hansson and Masucci, {Giuseppe V.} and Rolf Kiessling",
year = "2013",
month = "9",
day = "1",
doi = "10.1158/2326-6066.CIR-13-0016",
language = "English",
volume = "1",
pages = "158--162",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production

AU - Pico de Coaña, Yago

AU - Poschke, Isabel

AU - Gentilcore, Giusy

AU - Mao, Yumeng

AU - Nyström, Maria

AU - Hansson, Johan

AU - Masucci, Giuseppe V.

AU - Kiessling, Rolf

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Blocking the immune checkpoint molecule CTL antigen-4 (CTLA-4) with ipilimumab has proven to induce long-lasting clinical responses in patients with metastatic melanoma. To study the early response that takes place after CTLA-4 blockade, peripheral blood immune monitoring was conducted in five patients undergoing ipilimumab treatment at baseline, three and nine weeks after administration of the first dose. Along with T-cell population analysis, this work was primarily focused on an in-depth study of the myeloid-derived suppressor cell (MDSC) populations. Ipilimumab treatment resulted in lower frequencies of regulatory T cells along with reduced expression levels of PD-1 at the nine-week time point. Three weeks after the initial ipilimumab dose, the frequency of granulocytic MDSCs was significantly reduced and was followed by a reduction in the frequency of arginase1-producing CD3(-) cells, indicating an indirect in trans effect that should be taken into account for future evaluations of ipilimumab mechanisms of action.

AB - Blocking the immune checkpoint molecule CTL antigen-4 (CTLA-4) with ipilimumab has proven to induce long-lasting clinical responses in patients with metastatic melanoma. To study the early response that takes place after CTLA-4 blockade, peripheral blood immune monitoring was conducted in five patients undergoing ipilimumab treatment at baseline, three and nine weeks after administration of the first dose. Along with T-cell population analysis, this work was primarily focused on an in-depth study of the myeloid-derived suppressor cell (MDSC) populations. Ipilimumab treatment resulted in lower frequencies of regulatory T cells along with reduced expression levels of PD-1 at the nine-week time point. Three weeks after the initial ipilimumab dose, the frequency of granulocytic MDSCs was significantly reduced and was followed by a reduction in the frequency of arginase1-producing CD3(-) cells, indicating an indirect in trans effect that should be taken into account for future evaluations of ipilimumab mechanisms of action.

UR - http://www.scopus.com/inward/record.url?scp=84896523643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896523643&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-13-0016

DO - 10.1158/2326-6066.CIR-13-0016

M3 - Article

VL - 1

SP - 158

EP - 162

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 3

ER -